NYSE:OCX
OncoCyte Corp Stock News
$2.48
+0.0400 (+1.64%)
At Close: Apr 26, 2024
OncoCyte Corp. to Host Earnings Call
06:30pm, Wednesday, 25'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 25, 2020 / OncoCyte Corp. (NYSE:OCX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 25, 2020 at 4:30 PM East
The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down
11:29am, Wednesday, 25'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord
The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus
12:00am, Sunday, 22'nd Mar 2020
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
Biotech stocks went on a roller...
Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced th
ONCOCYTE TO REPORT FOURTH QUARTER AND FISCAL 2019 FINANCIAL RESULTS ON WEDNESDAY, MARCH 25
12:00pm, Wednesday, 18'th Mar 2020
IRVINE, Calif., March 18, 2020 -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision.
Oncocyte Closes Merger Agreement to Acquire Insight Genetics
01:00pm, Wednesday, 05'th Feb 2020
Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced th
Oncocyte Announces Relocation of its Headquarters to Orange County, California
01:00pm, Thursday, 30'th Jan 2020
Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced
DDD, NVTA among premarket gainers
02:27pm, Monday, 13'th Jan 2020
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors.Verona Pharma PLC (NASDAQ:VRNA) +54% on positive ensifentrine data.Mereo BioP
Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the lung cancer care continuum, today announc
Oncocyte Announces Definitive Agreement to Acquire Insight Genetics
09:05pm, Friday, 10'th Jan 2020
OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the lung cancer care continuum, today annou